Oestrogen receptor positive (ER+) means cancer cells have proteins that bind oestrogen, fueling their growth. This status determines whether hormone therapy is effective and influences survival rates. About 75% of breast cancers are ER+.
ER+ status is determined through a biopsy. Pathologists test tumor tissue using immunohistochemistry (IHC), which detects the presence of oestrogen receptors. A score of 0 to 100 indicates how many cells express the receptor. A score of 10 or higher is considered positive, according to the American Society of Clinical Oncology (ASCO).
When oestrogen binds to these receptors, it triggers signals that cause cell division. In ER+ tumors, blocking this signal slows or stops growth. This mechanism is the foundation of hormone therapy, the primary treatment for ER+ disease.
Doctors assess ER status during pathology review after a breast biopsy or surgery. The test uses antibodies that attach to oestrogen receptors in the sample. A color change confirms presence. Results are reported as a percentage of cells with receptors and a score (e.g., 90% positive, score 90).
Testing is standardized. The College of American Pathologists (CAP) guidelines require labs to use validated antibodies and controls. False negatives occur in 5-10% of cases due to sampling error or lab variability, so results are interpreted alongside clinical context.
A 2021 study in *JAMA Oncology* found that patients with ER+ tumors had a 10-year survival rate of 86%, compared to 72% for ER-negative cases. This difference underscores the importance of accurate testing.
Breast cancer is classified by hormone receptor status. The main categories are:
| Status | Receptor Expression | Treatment Implication | Prevalence |
|---|---|---|---|
| ER+/PR+ | Oestrogen and progesterone receptors present | Hormone therapy effective | 60% |
| ER+/PR− | Oestrogen receptor positive, progesterone negative | Still benefits from hormone therapy | 15% |
| ER−/PR+ | Oestrogen negative, progesterone positive | Rare; may respond to progestin therapy | 2% |
| ER−/PR− | Neither receptor present | No benefit from hormone therapy | 23% |
ER+ tumors often grow slower than ER-negative ones. They're more likely to be detected early and respond well to treatment. However, they can recur years later, requiring long-term monitoring.
One non-obvious fact: ER+ tumors can evolve. Some initially ER+ cancers lose receptors over time, becoming resistant to hormone therapy. This phenomenon, called receptor loss, occurs in 10-20% of cases after 5 years of treatment, per a 2020 study in *Nature Medicine*.
ER+ status improves prognosis. Patients with ER+ breast cancer have better five- and ten-year survival rates than those with ER-negative disease. This is because ER+ tumors tend to be less aggressive and respond to targeted treatments.
Treatment typically includes hormone therapy. Options include tamoxifen (for premenopausal women), aromatase inhibitors (for postmenopausal women), and ovarian suppression in younger patients. These drugs reduce oestrogen levels or block receptors.
For example, a 52-year-old woman diagnosed with stage II ER+ breast cancer received tamoxifen daily for five years. Her tumor shrank by 60% after four months of treatment. She remains in remission after seven years, with no signs of recurrence. This outcome reflects the effectiveness of hormone therapy in ER+ cases.
Combining hormone therapy with chemotherapy improves outcomes in high-risk ER+ patients. The ATLAS trial showed a 10% reduction in recurrence risk with extended tamoxifen use beyond five years.
Some people assume ER+ means the cancer is "mild" or "not serious." That's incorrect. While ER+ tumors grow slower, they still require treatment. Delaying care increases the risk of metastasis.
Another misconception: ER+ means oestrogen caused the cancer. Not necessarily. Oestrogen fuels existing cancer cells but doesn't initiate most cases. Risk factors include genetics, age, obesity, and hormonal exposure, not direct causation by oestrogen.
Patients sometimes confuse ER+ with HER2-positive status. These are distinct markers. HER2-positive cancers overexpress a different protein (HER2) and require targeted drugs like trastuzumab. About 15% of ER+ cancers are also HER2-positive, requiring dual therapy.
I've seen patients misinterpret their ER+ result as a sign of personal failure. One woman told me she felt guilty for "feeding" her cancer with oestrogen. I clarified that oestrogen is a natural hormone, not a dietary trigger. The condition is biological, not behavioral.
After receiving an ER+ diagnosis, patients should discuss treatment with an oncologist. Decisions depend on tumor size, grade, lymph node involvement, and menopausal status. Adjuvant therapy is standard unless the cancer is very low risk.
Genomic tests like Oncotype DX help predict recurrence risk. For ER+ early-stage cancer, a low Recurrence Score (<26) suggests chemotherapy adds little benefit. High scores (>31) indicate need for chemo plus hormone therapy.
ER+ status is not a life sentence. With proper treatment, many live long, healthy lives. Advances in hormone therapy continue to improve outcomes. Early detection and personalized care remain key.